Estrogen therapy: route matters.
Estrogen is the active ingredient of menopausal hormone therapy. How it enters the body — through the skin, by mouth, or locally — changes its risk profile more than most patients are ever told.
Oral or transdermal — does it matter?
Often, yes. Oral estrogen passes through the liver before reaching the bloodstream, which raises clotting factors, triglycerides, and inflammatory markers. Transdermal estrogen — a patch, gel, or spray — bypasses this first-pass effect and has a more favorable cardiovascular and venous-thrombosis profile.
We usually prefer transdermal delivery when any of the following are present: a personal or family history of venous thromboembolism, hypertension, controlled diabetes, obesity, hypertriglyceridemia, migraine with aura — or simply a desire to minimize cardiovascular risk. For a woman in her early 50s with no risk factors, oral and transdermal are both reasonable, and preference matters.
Vaginal estrogen is its own category
Low-dose vaginal estrogen — cream, tablet, insert, or ring — treats genitourinary symptoms locally with minimal systemic absorption. It carries no measurable increase in breast cancer risk and is often appropriate even for women who cannot use systemic therapy, in consultation with oncology where relevant. It is one of the most effective and most underused treatments in menopause medicine.
Dosing and monitoring
We start at a dose matched to your symptoms and history, reassess at about three months, and adjust by response. For symptom control we treat the patient, not the lab value — routine estradiol levels are not the guide; how you feel is. Re-evaluation of the risk–benefit balance is built into every annual visit.